Mecamylamine hydrochloride

Cat. No.: HY-B1395 Purity: ≥98.0%: FAQs
Data Sheet SDS COA Handling Instructions

Mecamylamine hydrochloride is an orally active, nonselective, noncompetitive nAChR antagonist. Mecamylamine hydrochloride is also a ganglionic blocker. Mecamylamine hydrochloride can across the blood-brain barrier. Mecamylamine hydrochloride can be used in the research of neuropsychiatric disorders, hypertension, antidepressant area.

For research use only. We do not sell to patients.

Mecamylamine hydrochloride Chemical Structure

CAS No. : 826-39-1

Size	Price	Stock	Quantity
Solution
10 mM * 1 mL in DMSO	USD 44	In-stock	Estimated Time of Arrival: December 31
Solid + Solvent
10 mM * 1 mL ready for reconstitution	USD 44	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 40	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 65	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 150	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 250	In-stock	Estimated Time of Arrival: December 31
100 mg		Get quote
200 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

Other Forms of Mecamylamine hydrochloride:

Mecamylamine Get quote

2 Publications Citing Use of MCE Mecamylamine hydrochloride

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

nAChR^[1], histamine receptor^[2]

In Vitro

Mecamylamine hydrochloride (0.5-9 μM, bath administered) increases the firing frequency of identified 5-HT DRN (dorsal raphe nucleus) neurons^[1].
? Mecamylamine hydrochloride (0.5-9 μM, bath administered) increases the glutamatergic and decreases the GABAergic input of 5-HT DRN neurons^[1].
? Mecamylamine hydrochloride (1 mM, 5 min) blocks the histamine receptor and the histamine-induced contractions in helically cut strips of rabbit aorta^[2].
? Mecamylamine hydrochloride (1-100 nM, 30 min) dose-dependently attenuates endothelial tube formation in HDMVECs^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[3]

Cell Line:	SCG neurons
Concentration:	10 μM
Incubation Time:	48 h
Result:	Reduced the nicotine-facilitated increase in ERK1/2.

In Vivo

Mecamylamine hydrochloride (subcutaneous pumps, 50 mg/kg/day, 2 days) inhibits Choroidal neovascularization (CNV) in CNV mice model^[4].
? Mecamylamine hydrochloride (intraperitoneal injection, 0.5-1 mg/kg) has antidepressant-like effects in both the TST (tail suspension test) and FST (forced swim test) in C57BL/6J mice, which are dependent on both β2 and α7 subunits^[5].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Choroidal neovascularization (CNV) mice model^[1]
Dosage:	50 mg/kg/day, 2 days
Administration:	Subcutaneous pumps implanted beneath the skin of the back, 200 μL and mean pumping rate of 0.5 μL/h.
Result:	Suppressed the development of CNV at Bruch’s membrane rupture sites in the absence of nicotine.

Animal Model:	C57BL/6J mice^[5]
Dosage:	0.5-1 mg/kg
Administration:	Intraperitoneal injection
Result:	Had no effect in β2 knockout mice and α7 knockout mice, but decreased immobility time in wildtype littermates in the FST.

Clinical Trial

Molecular Weight

203.75

Appearance

Solid

Formula

C₁₁H₂₂ClN

CAS No.

826-39-1

SMILES

CC1(C)C(NC)(C)C2CCC1C2.[H]Cl

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H₂O : 100 mg/mL (490.80 mM; Need ultrasonic)

DMSO : 31.25 mg/mL (153.37 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.9080 mL	24.5399 mL	49.0798 mL
5 mM	0.9816 mL	4.9080 mL	9.8160 mL
10 mM	0.4908 mL	2.4540 mL	4.9080 mL

*Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (10.21 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (10.21 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (10.21 mM); Clear solution

*All of the co-solvents are available by MCE.

Purity & Documentation

Purity: ≥98.0%

Select Batch:

Data Sheet (284 KB) SDS (419 KB)

COA (255 KB)

Handling Instructions (2659 KB)

References

[1]. Omar Hernández-González, et al. Mechanisms of stimulatory effects of mecamylamine on the dorsal raphe neurons. Brain Res Bull. 2020 Nov;164:289-298. [Content Brief]

[2]. C P Robinson, et al. The influence of mecamylamine on contractions induced by different agonists and on the role of calcium ions in the isolated rabbit aorta. J Pharmacol Exp Ther. 1976 Apr;197(1):57-65. [Content Brief]

[3]. Mahadevappa P Badanavalu, et al. Nicotine is neuroprotective to neonatal neurons of sympathetic ganglion in rat. Auton Neurosci. 2019 Jan;216:25-32. [Content Brief]

[4]. Katsuji Kiuchi, et al. Mecamylamine suppresses Basal and nicotine-stimulated choroidal neovascularization. Invest Ophthalmol Vis Sci. 2008 Apr;49(4):1705-11. [Content Brief]

[5]. Rabenstein RL, et al. The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not beta2- or alpha7-nicotinic acetylcholine receptor subunit knockout mice. Psychopharmacology (Berl). 2006 Dec;189(3):395-401. [Content Brief]